This article summarized the latest R&D progress of granisetron hydrochloride, the Mechanism of Action for granisetron hydrochloride, and the drug target R&D trends for granisetron hydrochloride.

Disease-Specific Survival (DSS) refers to deaths caused specifically by a particular disease.

Nature reported on a discovery by AbbVie, the Broad Institute, and Calico Life Sciences. Their research indicates the potential of ABBV-CLS-484, an experimental drug, to act as a PTPN2/N1 phosphatase inhibitor boosting anti-cancer immunity, orally administered.

Milestone survival rate is defined as the survival probability at a given point in time.

This article summarized the latest R&D progress of imiglucerase, the Mechanism of Action for imiglucerase, and the drug target R&D trends for imiglucerase.

Moderna, Inc. reported encouraging preliminary outcomes from the mRNA-1083 Phase 1/2 study, a combination vaccine currently under investigation for its effect against both influenza and COVID-19.

This article summarized the latest R&D progress of infliximab-abda, the Mechanism of Action for infliximab-abda, and the drug target R&D trends for infliximab-abda.

Health-Related Quality of Life (HRQoL) is a significant indicator for assessing the quality of life and health status of patients.

Circular RNA (circRNA) is a type of single-stranded RNA with a closed loop structure, initially found in HDV and plant viruses.

Vedanta Biosciences recently reported the initiation of treatment for the initial participant in the COLLECTiVE202 Phase 2 investigation of VE202.

This article summarized the latest R&D progress of eflornithine hydrochloride, the Mechanism of Action for eflornithine hydrochloride, and the drug target R&D trends for eflornithine hydrochloride.

Clinical Benefit Rate (CBR) is defined as the percentage of advanced cancer patients who achieve complete remission, partial remission, or at least six months of stable disease after treatment.